REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study (ICH03)

Overview

About this study

The purpose of this study is to determine if surgical clot reduction after ICH reduces the risk of progressive cognitive decline. Also, to determine if there is a long-term benefit in survival and functional outcome from minimally invasive surgery whether or not cognitive decline occurs.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Participants in the study must be survivors enrolled in MISTIE III and ENRICH trials at end of each trial's final follow-up (day 365 in MISTIE III and day 180 in ENRICH). Relatives of known survivors that are found to be deceased since the end of each trial will be interviewed to capture relevant data.

Exclusion Criteria: 

  • Not enrolled in MISTIE III or ENRICH trials. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/28/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

William Freeman, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions